报告题目：创新药的发现：基础到临床
报告专家：朱依谆 教授
报告时间：2022年11月19日（星期六）上午9：00
报告形式：Zoom直播（会议号：645 812 3884，密码：502502）
报告人简介：
Zhu Yi Zhun, Ph.D.
He is currently the Associate Vice President of Macau University of Science and Technology, Dean of the School of Pharmacy, Chair Professor, Physician of Internal Medicine at the University Hospital. He graduated from the Medical School, Shanghai Jiaotong University and received his Ph.D. from Heidelberg University, Germany. He is concurrently serving as Vice President of Macau Chinese Medical Association, Vice President of Macau Chinese Traditional Medicine Association, Vice President of World Federation of Traditional Chinese Medicine, member of State Pharmacopoeia Committee, member of Innovation Committee of Overseas Chinese Affairs Office of the State Council, and Editor-in-chief of "Chinese Clinical Drugs" (first edition), editor-in-chief of the national planning textbook "Pharmacology" (seventh and eighth editions and English first edition) of the national medical colleges and universities. He had served as Dean of School of Pharmacy, Fudan University for nearly 10 years, Distinguished Professor of Changjiang Scholars of the Ministry of Education, tier 1 Scientist of the National Major Research Program (973), recipient of the National Science Fund for Distinguished Young Scholars, and Shanghai Magnolia Honor Award recipient, Adjunct Professor at the National University of Singapore and the 8th President of the International Society for Natural Products Development (ISNPD). Professor Zhu Yi Zhun has been engaged in basic and clinical research on cardiovascular and cerebrovascular, inflammatory and immune mechanisms and anti-aging for a long time. He has successively presided over the 973 Project, the projects in National Natural Science Foundation of China with a total of 180 million funds in place. Professor Zhu Yi Zhun has published more than 330 scientific papers, which have been cited more than 15,300 times (h-index 67, i10 index 228). He has earned 38 invention patents. He was rated as one of the pioneers of new drug research in China by the American Science Journal. Ranked among the world's top 100,000 scientists and Stanford University's top 2% of the world's top scientists.
